2025
Second Malignancies among Older Patients with Classical Myeloproliferative Neoplasms Treated with Ruxolitinib
Wang R, Stempel J, Shallis R, Huntington S, Zeidan A, Neparidze N, Di M, Bewersdorf J, Mendez L, Ma X, Podoltsev N. Second Malignancies among Older Patients with Classical Myeloproliferative Neoplasms Treated with Ruxolitinib. Blood Neoplasia 2025, 100159. DOI: 10.1016/j.bneo.2025.100159.Peer-Reviewed Original ResearchSecond malignanciesMyeloproliferative neoplasmsOlder patientsEssential thrombocythemiaPolycythemia veraPhiladelphia chromosome-negative myeloproliferative neoplasmsDevelopment of second malignanciesRisk of non-melanoma skin cancerEnd Results Medicare-linked databaseNon-melanoma skin cancerMedian Follow-UpMedicare-linked databaseTherapy-related effectsRetrospective cohort analysisRisk of SMHazards regression modelsProportion of daysRuxolitinib exposureMedian ageFollow-upRuxolitinibCohort analysisSkin cancerPatientsMyelofibrosis
2024
Use of Calcineurin Inhibitor (CNI) and Eltrombopag (EPAG) Among Patients with Acquired Aplastic Anemia (AA) in the United States: Results from a Large National Database
Stempel J, Wang R, Lee A, Ma X, Podoltsev N. Use of Calcineurin Inhibitor (CNI) and Eltrombopag (EPAG) Among Patients with Acquired Aplastic Anemia (AA) in the United States: Results from a Large National Database. Blood 2024, 144: 2319. DOI: 10.1182/blood-2024-202185.Peer-Reviewed Original ResearchHorse anti-thymocyte globulinLow transfusion burdenAcquired Aplastic AnemiaCalcineurin inhibitor levelsCalcineurin inhibitorsSevere AARed blood cellsEltrombopag therapyTransfusion burdenMedian proportion of daysTransfusion of red blood cellsCalcineurin inhibitor agentsMedian starting doseAnti-thymocyte globulinDiagnosis to initiationTransplant-ineligible patientsBone marrow failureRare autoimmune disorderReduce transfusion requirementsBaseline red blood cellRetrospective cohort studyStudent's t-testProportion of daysBlue Cross Blue ShieldElixhauser comorbidity score
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply